TLPH|Talphera Inc|Price:0.848|Chg%:-0.05

More Details of Talphera Inc Company

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

Talphera Inc Info



Ticker SymbolTLPH

Company nameTalphera Inc

IPO dateFeb 11, 2011

CEOAngotti (Vincent J)

Number of employees13

Security typeOrdinary Share

Fiscal year-endFeb 11

Address1850 Gateway Drive

CitySAN MATEO

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code94404

Phone16502163500

Websitehttps://talphera.com/

Ticker SymbolTLPH

IPO dateFeb 11, 2011

CEOAngotti (Vincent J)

Company Executives of Talphera Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Badri N. Dasu

Chief Engineering Officer

45.03K

-5.43%

Dr. Shakil Aslam

Chief Development Officer, Chief Medical Officer

25.39K

-205.17%

Mr. Adrian Adams

Independent Chairman of the Board

13.34K

-31.98%

Mr. Joseph (Joe) Todisco

Director

6.40K

--

Mr. Mark Allen Wan

Independent Director

4.59K

-92.92%

Mr. Abhinav (Abi) Jain

Independent Director

2.75K

-144.41%

Dr. Stephen J. Hoffman, M.D., Ph.D.

Independent Director

--

Mr. Vincent J. (Vince) Angotti

Chief Executive Officer, Director

--

Mr. Raffi M. Asadorian

Chief Financial Officer

--

Ms. Marina S. Bozilenko

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Badri N. Dasu

Chief Engineering Officer

45.03K

-5.43%

Dr. Shakil Aslam

Chief Development Officer, Chief Medical Officer

25.39K

-205.17%

Mr. Adrian Adams

Independent Chairman of the Board

13.34K

-31.98%

Mr. Joseph (Joe) Todisco

Director

6.40K

--

Mr. Mark Allen Wan

Independent Director

4.59K

-92.92%

Mr. Abhinav (Abi) Jain

Independent Director

2.75K

-144.41%

Revenue Breakdown

Currency: USDUpdated: Mar 5, 2025

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

By BusinessUSD

Name

Revenue

Proportion

DSUVIA

1.59M

89.67%

DZUVEO

183.00K

10.33%

Zalviso

0.00

0.00%

Non-cash royalty revenue related to Royalty Monetization

0.00

0.00%

Other revenue

0.00

0.00%

Other

0.00

0.00%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

DSUVIA

1.59M

89.67%

DZUVEO

183.00K

10.33%

Zalviso

0.00

0.00%

Non-cash royalty revenue related to Royalty Monetization

0.00

0.00%

Other revenue

0.00

0.00%

Other

0.00

0.00%

Shareholding Stats

Updated: Thu, May 14

Shareholders

Shareholder Types

Shareholders

Proportion

CorMedix Inc

17.52%

Rock Springs Capital Management LP

6.92%

Rosalind Advisors, Inc.

6.90%

AIGH Capital Management, LLC.

6.55%

Lytton (Laurence W)

5.26%

Other

56.86%

Shareholders

Proportion

CorMedix Inc

17.52%

Rock Springs Capital Management LP

6.92%

Rosalind Advisors, Inc.

6.90%

AIGH Capital Management, LLC.

6.55%

Lytton (Laurence W)

5.26%

Other

56.86%

Shareholder Types

Shareholders

Proportion

Corporation

17.52%

Hedge Fund

15.02%

Individual Investor

6.73%

Private Equity

6.55%

Investment Advisor

4.89%

Investment Advisor/Hedge Fund

4.38%

Research Firm

0.44%

Other

44.47%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

68

20.36M

40.00%

+746.54K

2025Q4

65

18.51M

39.72%

+8.77M

2025Q3

65

12.68M

31.11%

+4.13M

2025Q2

79

6.96M

33.93%

-506.98K

2025Q1

82

6.66M

34.60%

-832.94K

2024Q4

84

5.24M

30.79%

-2.31M

2024Q3

100

5.33M

31.39%

-2.35M

2024Q2

109

5.51M

32.40%

-2.29M

2024Q1

113

5.56M

32.76%

-881.00K

2023Q4

117

5.91M

35.12%

-445.19K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

CorMedix Inc

9.09M

18.16%

+9.09M

--

Sep 10, 2025

Rock Springs Capital Management LP

3.59M

7.17%

--

Dec 31, 2025

Rosalind Advisors, Inc.

3.58M

7.15%

-806.48K

-18.39%

Dec 31, 2025

AIGH Capital Management, LLC.

3.40M

6.79%

+382.48K

+12.69%

Dec 31, 2025

Lytton (Laurence W)

2.73M

5.46%

-905.65K

-24.91%

Dec 31, 2025

Worth Venture Partners, LLC

1.26M

2.53%

-175.52K

-12.19%

Dec 31, 2025

Bleichroeder LP

881.17K

1.76%

--

Dec 31, 2025

Angotti Vincent J

674.09K

1.35%

+213.31K

+46.29%

Mar 13, 2026

Empery Asset Management, L.P.

1.33M

2.66%

+1.33M

--

Dec 31, 2025

Cantor Fitzgerald, L.P

577.49K

1.15%

+577.49K

--

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

iShares Core S&P Total U.S. Stock Market ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Oct 25, 2022

Merger

20→1

Oct 25, 2022

Merger

20→1

Oct 25, 2022

Merger

20→1

Oct 25, 2022

Merger

20→1

Date

Ex-dividend Date

Type

Ratio

Oct 25, 2022

Merger

20→1

Oct 25, 2022

Merger

20→1

Oct 25, 2022

Merger

20→1

Oct 25, 2022

Merger

20→1